@chuk
apologies yes you are right venetoclax more for lymphoma and not AML. There are other drugs in AML though that are showing promise in phase I (I think IDH1 inhibitors). I was trying to make a general point rather than a specific one (ie you have to compare why people would prescribe this drug over other drugs in clinical trial pipeline).
if you really want to know what drugs are in the pipeline as competition you can try to search for abstracts for AML at ASH later this year.
@chukapologies yes you are right venetoclax more for lymphoma...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.030(2.10%) |
Mkt cap ! $238.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.46 | $1.38 | $123.1K | 87.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19987 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 330 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |